JonesTrading Upgrades Western Asset Mortgage to Buy

JonesTrading analyst Jason Stewart upgrades Western Asset Mortgage (NYSE:WMC) from Hold to Buy.

byBenzinga Newsdesk

June 13, 2022

1 minute read

JonesTrading analyst Jason Stewart upgrades Western Asset Mortgage (NYSE:WMC) from Hold to Buy.

Universal Logistics Hldgs Q1 EPS $1.56 Beats $0.72 Estimate, Sales $523.90M Beat $443.60M Estimate

By Benzinga Newsdesk

Today, 2:08 AM

Universal Logistics Hldgs (NASDAQ:ULH) reported quarterly earnings of $1.56 per share which beat the analyst consensus estimate of $0.72 by 116.67 percent. This is a 95 percent increase over earnings of $0.80 per share

ULH

Events
News

Canopy Growth CEO To Deliver Keynote Presentation At Benzinga’s Cannabis Capital Conference Apr. 20, 2022

By Benzinga Newsdesk

Today, 2:08 AM

Benzinga, a financial news and data company recently acquired at a$300 million valuation, announced that the CEO of Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED)

CGC

$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,100 Today

By Benzinga Insights

Today, 2:08 AM

America Movil (NYSE:AMX) has outperformed the market over the past 20 years by 4.4% on an annualized basis producing an average annual return of 11.47%. Currently, America Movil has a market capitalization of $65.06 billion.

AMX

Incyte Corporation Announces Late Wednesday Phase 3 Data Showing Improvements In Facial And Total Body Repigmentation With Ruxolitinib Cream In Vitiligo Published In New England Journal Of Medicine

By Benzinga Newsdesk

Today, 2:08 AM

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two

INCY

JonesTrading Upgrades Western Asset Mortgage to Buy

Related Posts

Universal Logistics Hldgs Q1 EPS $1.56 Beats $0.72 Estimate, Sales $523.90M Beat $443.60M Estimate

Canopy Growth CEO To Deliver Keynote Presentation At Benzinga’s Cannabis Capital Conference Apr. 20, 2022

$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,100 Today

Incyte Corporation Announces Late Wednesday Phase 3 Data Showing Improvements In Facial And Total Body Repigmentation With Ruxolitinib Cream In Vitiligo Published In New England Journal Of Medicine